company background image
600993 logo

Mayinglong Pharmaceutical Group SHSE:600993 Stock Report

Last Price

CN¥26.07

Market Cap

CN¥11.3b

7D

-3.1%

1Y

11.3%

Updated

18 Dec, 2024

Data

Company Financials +

Mayinglong Pharmaceutical Group Co., Ltd.

SHSE:600993 Stock Report

Market Cap: CN¥11.3b

My Notes

Capture your thoughts, links and company narrative

Mayinglong Pharmaceutical Group Co., Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Mayinglong Pharmaceutical Group
Historical stock prices
Current Share PriceCN¥26.07
52 Week HighCN¥31.18
52 Week LowCN¥20.20
Beta0.58
1 Month Change4.49%
3 Month Change19.04%
1 Year Change11.32%
3 Year Change-6.83%
5 Year Change51.31%
Change since IPO1,043.45%

Recent News & Updates

Estimating The Intrinsic Value Of Mayinglong Pharmaceutical Group Co., Ltd. (SHSE:600993)

Oct 01
Estimating The Intrinsic Value Of Mayinglong Pharmaceutical Group Co., Ltd. (SHSE:600993)

What Mayinglong Pharmaceutical Group Co., Ltd.'s (SHSE:600993) P/E Is Not Telling You

Aug 19
What Mayinglong Pharmaceutical Group Co., Ltd.'s (SHSE:600993) P/E Is Not Telling You

Recent updates

Estimating The Intrinsic Value Of Mayinglong Pharmaceutical Group Co., Ltd. (SHSE:600993)

Oct 01
Estimating The Intrinsic Value Of Mayinglong Pharmaceutical Group Co., Ltd. (SHSE:600993)

What Mayinglong Pharmaceutical Group Co., Ltd.'s (SHSE:600993) P/E Is Not Telling You

Aug 19
What Mayinglong Pharmaceutical Group Co., Ltd.'s (SHSE:600993) P/E Is Not Telling You

Mayinglong Pharmaceutical Group's (SHSE:600993) Shareholders Will Receive A Bigger Dividend Than Last Year

Jul 24
Mayinglong Pharmaceutical Group's (SHSE:600993) Shareholders Will Receive A Bigger Dividend Than Last Year

Mayinglong Pharmaceutical Group (SHSE:600993) Has A Rock Solid Balance Sheet

Jun 19
Mayinglong Pharmaceutical Group (SHSE:600993) Has A Rock Solid Balance Sheet

Mayinglong Pharmaceutical Group Co., Ltd.'s (SHSE:600993) Price Is Right But Growth Is Lacking After Shares Rocket 26%

May 07
Mayinglong Pharmaceutical Group Co., Ltd.'s (SHSE:600993) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Investors Don't See Light At End Of Mayinglong Pharmaceutical Group Co., Ltd.'s (SHSE:600993) Tunnel

Mar 22
Investors Don't See Light At End Of Mayinglong Pharmaceutical Group Co., Ltd.'s (SHSE:600993) Tunnel

Shareholder Returns

600993CN PharmaceuticalsCN Market
7D-3.1%-2.8%-2.6%
1Y11.3%-3.9%9.7%

Return vs Industry: 600993 exceeded the CN Pharmaceuticals industry which returned -3.9% over the past year.

Return vs Market: 600993 exceeded the CN Market which returned 9.7% over the past year.

Price Volatility

Is 600993's price volatile compared to industry and market?
600993 volatility
600993 Average Weekly Movement5.8%
Pharmaceuticals Industry Average Movement7.4%
Market Average Movement8.7%
10% most volatile stocks in CN Market12.8%
10% least volatile stocks in CN Market5.8%

Stable Share Price: 600993 has not had significant price volatility in the past 3 months compared to the CN market.

Volatility Over Time: 600993's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
15822,882Youzhang Xiawww.mayinglong.cn

Mayinglong Pharmaceutical Group Co., LTD. engages in the manufacture, wholesale, and retail of pharmaceutical products primarily in China. The company products pipeline primarily consists of functional cosmetics, functional care products, functional food, and Chinese herbal medicines, as well as hemorrhoid, gynecological, cough, and skin products; and medical instruments.

Mayinglong Pharmaceutical Group Co., Ltd. Fundamentals Summary

How do Mayinglong Pharmaceutical Group's earnings and revenue compare to its market cap?
600993 fundamental statistics
Market capCN¥11.27b
Earnings (TTM)CN¥482.37m
Revenue (TTM)CN¥3.48b

23.3x

P/E Ratio

3.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
600993 income statement (TTM)
RevenueCN¥3.48b
Cost of RevenueCN¥1.90b
Gross ProfitCN¥1.58b
Other ExpensesCN¥1.10b
EarningsCN¥482.37m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)1.12
Gross Margin45.37%
Net Profit Margin13.85%
Debt/Equity Ratio4.0%

How did 600993 perform over the long term?

See historical performance and comparison

Dividends

1.5%

Current Dividend Yield

36%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/18 10:29
End of Day Share Price 2024/12/18 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Mayinglong Pharmaceutical Group Co., Ltd. is covered by 16 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jun LiuChangjiang Securities Co. LTD.
Ling Bo TuChina Minzu Securities
Bing ZhaoChina Renaissance Securities